



SATURDAY, OCTOBER 26, 2019

12:30 - 1:30 p.m.

Montreal Convention Centre

Room: 517C

Aspirin, DAPT or dual pathway inhibition for secondary prevention in stable ASCVD patients?

FACULTY

SHAMIR R. MEHTA
(Chair)
MD, MSc, FRCPC, FACC, FESC

EVA LONN
MD, MSc, FRCPC, FACC

ROBERT WELSH
MD, FRCPC, FACC, FAHA, FESC

JACOB A. UDELL
(Co-Chair)
MD, MPH, FRCPC

JEAN-FRANÇOIS TANGUAY
MD, FRCPC, FCCS, FACC,
FAHA, FESC

GRAHAM C. WONG
MD, MPH, FRCPC, FACC,
FCCS, FAHA

AGENDA

12:30 - 12:35 p.m.	Welcome and Introductions	Dr. Shamir R. Mehta, Chair
12:35 - 12:40 p.m.	It's time to overcome inertia in "stable" atherosclerotic CV disease	Dr. Eva Lonn
12:40 - 12:50 p.m.	Debate: Be it resolved, in stable ASCVD patients, aspirin is enough	PRO: Dr. Jacob A. Udell CON: Dr. Robert Welsh
12:50 - 12:55 p.m.	Case Study Chronic CAD: Is stable ever truly stable? The case for changing the standard secondary prevention playbook	Dr. Graham C. Wong
12:55 - 1:08 p.m.	Panel Discussion and Q&A	All
1:08 - 1:13 p.m.	Case Study Post-ACS with Stents: What are the options for the clinician?	Dr. Jean-François Tanguay
1:13 - 1:25 p.m.	Panel Discussion and Q&A	All
1:25 - 1:30 p.m.	Closing Remarks	Dr. Jacob A. Udell, Co-Chair

LEARNING OBJECTIVES

After completing the symposium, participants will be able to:

- Recognize the risk of recurrent events in patients with atherosclerotic cardiovascular disease using case-based scenarios
- Assess the appropriateness of long-term antithrombotic regimen options for different patient types by reviewing the most recent evidence available
- Determine which patients should be transitioned from DAPT to the COMPASS regimen
- Recognize and quantify the risk of recurrent events in patients with atherosclerotic cardiovascular disease
- Understand the benefits and risks of aspirin, dual pathway inhibition, or dual antiplatelet therapy as the top line long-term antithrombotic therapy in stable patients
- Define the optimal long-term antithrombotic regimen for stable patients with coronary artery disease
- Define the optimal long-term antithrombotic regimen for stable patients post-ACS who underwent PCI with stenting



Canadian Cardiovascular Society

Leadership. Knowledge. Community.

This event is an accredited Group Learning Activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was co-developed with the Canadian Cardiovascular Society and Bayer Inc. and was planned to achieve scientific integrity, objectivity and balance. This program was made possible through an educational grant from Bayer Inc.